Xencor develops engineered antibody drugs for cancer and autoimmune diseases and partners with other drugmakers on its technology. It last closed at $34.50 on Nov 17, down 2.55% on the day. The average 12-month price target from 9 analysts is $41.11 (+19.2% from the last close), with a high of $70.00 and a low of $21.00. Analyst consensus is Strong Buy, based on the latest ratings from 9 firms (7 buy, 2 hold, 0 sell).
Each firm's latest rating on XNCR in the past 90 days
Average 12-month target
$41.11
▲ 19.2% upside
Based on 9 analysts who set a price target on XNCR in the past 90 days. The average target is $41.11, with a high of $70.00 and a low of $21.00, compared with the last close of $34.50.
Low $21.00Avg $41.11High $70.00
Blue marker: last close $34.50
Highest target$70.00
Average target$41.11
Lowest target$21.00
Latest rating changes
Cantor FitzgeraldTarget raised
Nov 5Buy$44 → $70
Truist SecuritiesTarget raised
Oct 27Buy$29 → $40
RBC CapitalTarget raised
Oct 27Buy$20 → $43
Wells FargoMaintained
Oct 27Buy$44
WedbushTarget raised
Oct 27Buy$30 → $45
Date
Firm
Action
Rating
Price target
Nov 5
Cantor Fitzgerald
Target raised
Buy
$44 → $70
Oct 27
Truist Securities
Target raised
Buy
$29 → $40
Oct 27
RBC Capital
Target raised
Buy
$20 → $43
Oct 27
Wells Fargo
Maintained
Buy
$44
Oct 27
Wedbush
Target raised
Buy
$30 → $45
Loading…
Technical Analysis
XNCR · as of the Nov 17 close · updated after every close
Uptrend
The stock is 5% above its 20 day and 20% above its 50 day average. It is 47% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 58). The nearest support is the Pivot S1 at $33.92, and the nearest resistance the Pivot at $34.81.
Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityNormal, 5.9%/day
Key levels
$40.5852 week high+17.6%
$40.58Swing high (Nov 11)+17.6%
$35.38Pivot R1+2.6%
$34.81Pivot+0.9%
$34.50Last close
$33.92Pivot S1−1.7%
$32.6320 day average−5.4%
$27.7050 day average−19.7%
$25.81Swing low (Aug 28)−25.2%
$24.49100 day average−29.0%
$18.33200 day average−46.9%
$10.3852 week low−69.9%
Indicators
RSI (14)
58.21
Middle of its range
Neutral
MACD
2.97
Above its signal line
Bullish
Stochastic
59.6
Middle of its range
Neutral
ADX (14)
39.1
Trending up
Williams %R
-50.8
Oversold below −80, overbought above −20
Neutral
CCI (20)
35.8
Oversold below −100, overbought above 100
Neutral
Rate of change
+12.6%
Change over 10 sessions
Bullish
ATR (14)
$2.02
Typical daily range, 5.9% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
Rising, overbought
Short trendBullish
Long trendNot enough history
MomentumStrong
StretchOverbought
VolatilityNormal, 10.2%/day
Key levels
$40.5852 week high+17.6%
$40.58Swing high (Nov 11)+17.6%
$35.38Pivot R1+2.6%
$34.81Pivot+0.9%
$34.50Last close
$33.92Pivot S1−1.7%
$32.6320 day average−5.4%
$27.7050 day average−19.7%
$25.81Swing low (Aug 28)−25.2%
$24.49100 day average−29.0%
$18.33200 day average−46.9%
$10.3852 week low−69.9%
Indicators
RSI (14)
72.37
Overbought above 70
Overbought
MACD
4.64
Above its signal line
Bullish
Stochastic
81.9
Near the top of its range
Overbought
ADX (14)
52.1
Strong uptrend
Williams %R
-32.7
Oversold below −80, overbought above −20
Neutral
CCI (20)
162.5
Oversold below −100, overbought above 100
Overbought
Rate of change
+41.3%
Change over 10 sessions
Bullish
ATR (14)
$3.52
Typical daily range, 10.2% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200–
What happened before, for XNCR
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how XNCR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow XNCR usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How XNCR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XNCR is in one of them and how their past XNCR trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Xencor
Xencor is a biopharmaceutical company based in Pasadena, California, that designs engineered antibody drugs. Its work focuses on cancer and autoimmune diseases, and it uses its own protein engineering technology to build antibody drug candidates, several of which are in clinical trials. The company also licenses its antibody design technology to pharmaceutical and biotechnology partners, who may develop or market the resulting medicines.